If this is your company, CONTACT US to activate Packbase™ software to build your portal.
The project, known as “MyCPS“, is to open up application areas to implement “Industrie 4.0” by showing how CPS can be shaped and implemented in a people-centred manner so that companies can use these systems to achieve their productivity potential. CPS (Cyber-Physiscal Systems) are systems which link the real world with the virtual one. They control and monitor processes by means of sensors and actuators, linking them with each other via the internet. In the vision of a fully realized “Industrie 4.0”, for example, orders will, via CPS, independently steer themselves through complete value-added chains, ordering materials and processing machinery, as well as organizing their delivery to the customers.
Christian Krätzig, Managing Director of H&T Presspart Marsberg comments: “Industrie 4.0 technologies can only be successful if employees are actively involved in their implementation.“ MyCPS focuses on this aspect.
H&T Presspart Marsberg will implement an interactive, decentralized and mobile solution to record, classify, assign, report, as well as analyze and eliminate faults in the production process. The focus will be on creating an intuitive user guide suitable for industrial use, as well as on interaction with employees. With the help of such interactive fault management, hand-written documentation of fault data and manual commissioning of maintenance work and measures to rectify faults will soon belong to the past.
H&T Presspart Marsberg belongs to the H&T Presspart Division of the Heitkamp & Thumann Group with its head office in Marsberg in the Sauerland region. With three European business locations, H&T Presspart is specialised in the manufacture of high-precision metal and plastic components for the pharmaceutical industry. The family-owned Heitkamp & Thumann Group comprises more than 20 medium-sized companies in 10 different countries with around 2000 employees, organized in two divisions and five independent business units.
“Industrie 4.0″ or the fourth industrial revolution is the German vision for the future of manufacturing and stands for the current trend of digital automation and data exchange in manufacturing technologies.
The research and development project for the implementation of people-centred Cyber-Physical Systems (MyCPS) is funded by the Federal Ministry of Education and Research (BMBF) through the funding programme “Industrie 4.0 – Research on the factory shop floor“ and supervised by the project agency Karlsruhe (PTKA).
Smart Inhalers- Improving Patient Compliance and Reducing Health Care Costs
H&T Presspart are pleased to announce that they have accepted an invitation to speak at the upcoming 14th Annual Congress of International Drug Discovery Science and Technology-South Korea 2016 (IDDST-South Korea 2016) which will be held at Geyonggi of South Korea during June 16-18, 2016.
Dana Shear’s, H&T Presspart’s Sales Director for the America’s will be delivering a 30 minute speech on Smart Inhalers-Improving Patient Compliance and Reducing Health Care Costs at 14.50 during day 3 of the conference on Saturday 18th June.
The abstract of the speech is:
Rising healthcare costs are a phenomenon across the developed world and can be attributed to a combination of factors, including ageing population, and the availability of more expensive healthcare treatments.
However, data also shows that patient adherence and compliance is a major contributor. In developed countries, adherence to long-term therapies in the general population is around 50% and is much lower in developing countries. Asthma and COPD are the 5th and 6th most costly conditions in the United States today estimated at over $50 billion annually, each.
The global number of asthma and COPD suffers is growing at annual rates of 3% and 7% respectively. Recent advances in technology is enabling users and prescribers of meter dose inhalers to more effectively monitor patient compliance and adherence, including remotely. Studies have shown that these new devices can lead to a reduction in healthcare costs by validating prescribed therapies, and confirming compliance and adherence, thereby, avoiding costly visits to physicians or hospitals.
The technology, benefits, and barriers associated with developing, registering and marketing these emerging “Smart Inhalers” will be presented and discussed.
Dana will also be on hand to discuss H&T Presspart’s recently announced Connected Metered Dose Inhaler, which has been developed in partnership with Cohero Health, a leading US based digital health focused company.
The eMDI incorporates electronics into a medication inhaler to passively track and communicate medication utilization. The device incorporates a sensor to track the date and time when medication is actuated, which is then stored in onboard memory, as well as shared wirelessly via Bluetooth. It works seamlessly with Cohero Health’s platform of connected devices and mobile applications, which actively engage and empower respiratory patients by tracking medication adherence and measuring lung function.
The companies believe the eMDI, which is available for demonstration, is the first functional connected MDI ever developed. Unique features include:
- Seamless integration into Cohero Health’s connected respiratory care platform
- Onboard sensors to detect medication use as well as quality of medication administration (detection of proper inhaler actuation)
- On board electronic dose counting and display
- Modular design enabling sensing and communication capabilities to be easily be applied to additional form factors
- Compatibility with any valve and canister
- Lack of disruption to medication delivery geometry, reducing regulatory pathway and time to market
H&T Presspart, the leading global supplier of MDI components to the pharmaceutical industry, have once again confirmed their attendance at the DDL27 (Drug Delivery to the Lungs) conference which is being held in Edinburgh from the 7-9 December 2016.
H&T Presspart will be a Silver Sponsor of the event and will be showcasing a number of new products to the market including their Connected Electronic Dose Counter and the Quantum Dose Indicator for metered-dose inhalers.
The Connected Electronic Dose Counter, which was developed in partnership with Cohero Health, incorporates electronics into a medication inhaler to passively track and communicate medication utilization. The device incorporates a sensor to track the date and time when medication is actuated, which is then stored in onboard memory, as well as shared wirelessly via Bluetooth.
It works seamlessly with Cohero Health’s platform of connected devices and mobile applications, which actively engage and empower respiratory patients by tracking medication adherence and measuring lung function.
As well as H&T Presspart’s standard range of MDI components, including metered-dose inhaler canisters and metered-dose inhaler actuators, H&T Presspart will also be promoting another innovative product, the Quantum Dose Indicator.
H&T Presspart’s patented Quantum end of life indicator has been developed to be a low cost, disposable dose indicator solution, ensuring patients don’t run out of their medication when they need it the most.
Quantum is built in to the MDI canister by H&T Presspart, and is compatible with current filling and packaging lines. The Quantum dose indicator system also features no mechanical parts, ensuring the patient has a fail-safe, robust and reliable end of life calibration system.
DDL 27 is the last respiratory drug delivery conference of the year, and as well as the exhibition area there is also a scientific conference programme and poster area. The conference runs from the 7-9 December and is held at the Edinburgh International Conference Centre, Scotland.
Cohero Health, a digital health company focused on developing connected health tools and technologies to empower respiratory patients and improve care through smart mobile devices, and H&T Presspart (a division of the German based Heitkamp & Thumann Group), a specialist medical device and pharmaceutical component manufacturer, are pleased to announce the completion of their connected metered dose inhaler (eMDI).
The eMDI incorporates electronics into a medication inhaler to passively track and communicate medication utilization. The device incorporates a sensor to track the date and time when medication is actuated, which is then stored in onboard memory, as well as shared wirelessly via Bluetooth. It works seamlessly with Cohero Health’s platform of connected devices and mobile applications, which actively engage and empower respiratory patients by tracking medication adherence and measuring lung function.
“We’re excited to announce the addition of the eMDI to the Cohero Health portfolio,” said Cohero Health CEO, Melissa Manice, PhD MPH. “Our company’s mission is to transform respiratory care through smart mobile devices. Early in our product development, we recognized the importance of including tracking and communication capabilities into the MDI. Our eMDI is the natural evolution ofConnected MDI our external medication sensors (HeroTrackers), and represents an exciting opportunity to better monitor adherence and quality of medication delivery, ultimately enabling improved medication use and prevention of avoidable exacerbations.”
The eMDI is the result of a multi-year development effort between Cohero Health and H&T Presspart. The relationship has resulted in production of functional devices, now readily available to the pharmaceutical industry.
“This partnership combines the strengths of two industry leaders. We saw a great opportunity to combine Cohero Health’s digital innovation with H&T Presspart’s expertise in MDI design and manufacturing. Together, we have developed an industry-leading offering. In addition to having a functional product, our capabilities as a manufacturer enable us to fully commercialize and supply this offering globally,” explained Peter Schmelzer, General Partner of the Heitkamp & Thumann Group and Chairman of H&T Presspart.
The companies believe the eMDI, which is available for demonstration, is the first functional connected MDI ever developed. Unique features include:
- Seamless integration into Cohero Health’s connected respiratory care platform
- Onboard sensors to detect medication use as well as quality of medication administration (detection of proper inhaler actuation)
- On board electronic dose counting and display
- Modular design enabling sensing and communication capabilities to be easily be applied to additional form factors
- Compatibility with any valve and canister
- Lack of disruption to medication delivery geometry, reducing regulatory pathway and time to market
The eMDI represents an advancement of the Cohero Health platform, which is already the first and only respiratory disease management platform to offer tracking of both controller and rescue medications, along with clinically accurate lung function measurement via an FDA cleared mobile spirometer.
“This announcement further demonstrates our commitment to leading innovation in respiratory care.” said Cohero Health Co-Founder and COO Daniel Weinstein. “The eMDI represents an exciting new tool for pharmaceutical companies to improve their product utilization, as well as enable unprecedented real-time monitoring of who is using their products, how they are using them, and how they are responding.”
The eMDI is available for commercialization, and the companies are currently in development with a number of pharmaceutical companies.